Boehringer Ingelheim


Concise Prescribing Info
Essential HTN. Reduction of the risk of MI, stroke or death in patients ≥55 yr at high risk developing major CV events who are unable to take ACE inhibitors. High risk CV events including evidence of CAD, peripheral arterial disease, stroke, transient ischemic attack or diabetes w/ evidence of end-organ damage. Additional treatment to antihypertensive, antiplatelet or lipid-lowering therapy.
Dosage/Direction for Use
Adult Essential HTN 40 mg once daily, may be increased to max: 80 mg once daily. Severe HTN 160 mg alone &/or in combination w/ hydrochlorothiazide 12.5-25 mg daily. CV risk reduction 80 mg once daily. Mild to moderate hepatic impairment Not to exceed 40 mg once daily.
May be taken with or without food.
Hypersensitivity. Biliary obstructive disorders. Concomitant use w/ aliskiren in patients w/ DM or renal impairment (GFR <60 mL/min/1.73 m2). Severe hepatic impairment. 2nd & 3rd trimesters of pregnancy. Lactation.
Special Precautions
Not recommended in primary aldosteronism. Patients w/ bilateral renal artery stenosis or artery stenosis to single functioning kidney, severe CHF or underlying renal disease including renal artery stenosis, aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy; biliary obstructive disorders; DM & CAD; ischaemic cardiopathy or CV disease. Correct vol &/or Na depletion prior to administration. Dual blockade of renin-angiotensin-aldosterone system. Concomitant use w/ K-sparing diuretics, K supplements, K-containing salt substitutes or other drugs increasing K level eg, heparin. Black patients. Fructose intolerance. Periodic monitoring of serum K & creatinine in patients w/ renal impairment. May affect ability to drive & use machines. Hepatic insufficiency. Not to be initiated during pregnancy. Not recommended during 1st trimester of pregnancy. Childn <18 yr.
Adverse Reactions
UTI including cystitis, upper resp tract infections, sepsis including fatal outcome; anaemia, eosinophilia, thrombocytopenia; anaphylactic reaction, hypersensitivity; hyperkalaemia, hypoglycaemia in diabetic patients; insomnia, depression, anxiety; syncope; visual disturbance; vertigo; bradycardia, tachycardia; hypotension, orthostatic hypotension; dyspnoea; abdominal pain, diarrhoea, dyspepsia, flatulence, vomiting, dry mouth, stomach discomfort; abnormal hepatic function/liver disorder; pruritus, hyperhidrosis, rash, angioedema w/ fatal outcome, eczema, erythema, urticaria, drug eruption, toxic skin eruption; back pain, muscle spasms, myalgia, arthralgia, pain in extremity, tendon pain; renal impairment including acute renal failure; chest pain, asthenia, influenza-like illness; increased hepatic enzymes, blood creatinine, uric acid & creatine phosphokinase, decreased Hb.
Drug Interactions
Increased hypotensive effect of other antihypertensives. Increased median plasma digoxin trough conc. Increased ramipril & ramiprilat AUC & Cmax. Reversible increased serum lithium conc & toxicity. Reduced antihypertensive effect w/ NSAIDs.
MIMS Class
Angiotensin II Antagonists
ATC Classification
C09CA07 - telmisartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.
Micardis tab 40 mg
Micardis tab 80 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in